EGFR-mutant NSCLC progressing on first-line osimertinib: rebiopsy in real-world and impact of second-line therapies (the "Rebiopsy on Osi" study).

Gariazzo E, Colamartini F, Cantale O, Mogavero A, Vitale A, Romano L, Peroni M, Rijavec E, Banini M, Mazzoni S, Montrone M, Pasello G, Veccia A, Ogliari FR, Leo S, Cortinovis D, Delmonte A, Belluomini L, La Cava G, Meoni G, Sini C, Delcuratolo MD, Bettini A, Pagano M, Genova C, Russo A, Pelizzari G, Tondulli L, Sergi C, Roca E, Bennati C, Grisanti S, Stanzione B, Mariotti S, Vavalà T, Soto Parra H, Ortega C, Pignataro D, Lacidogna G, Pino MS, Chiari R, Calabrò L, Pozzessere D, Masini S, Gelibter A, Scotti V, Grossi F, Tiseo M, Bria E, Metro G

Open source

DOI
10.1093/oncolo/oyag285
Published
2026 Aug 6
Container
The oncologist
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1093/oncolo/oyag285,
  title = {EGFR-mutant NSCLC progressing on first-line osimertinib: rebiopsy in real-world and impact of second-line therapies (the "Rebiopsy on Osi" study).},
  author = {Gariazzo E and Colamartini F and Cantale O and Mogavero A and Vitale A and Romano L and Peroni M and Rijavec E and Banini M and Mazzoni S and Montrone M and Pasello G and Veccia A and Ogliari FR and Leo S and Cortinovis D and Delmonte A and Belluomini L and La Cava G and Meoni G and Sini C and Delcuratolo MD and Bettini A and Pagano M and Genova C and Russo A and Pelizzari G and Tondulli L and Sergi C and Roca E and Bennati C and Grisanti S and Stanzione B and Mariotti S and Vavalà T and Soto Parra H and Ortega C and Pignataro D and Lacidogna G and Pino MS and Chiari R and Calabrò L and Pozzessere D and Masini S and Gelibter A and Scotti V and Grossi F and Tiseo M and Bria E and Metro G},
  year = {2026},
  journal = {The oncologist},
  doi = {10.1093/oncolo/oyag285},
  url = {https://doi.org/10.1093/oncolo/oyag285}
}

RIS

TY  - JOUR
TI  - EGFR-mutant NSCLC progressing on first-line osimertinib: rebiopsy in real-world and impact of second-line therapies (the "Rebiopsy on Osi" study).
AU  - Gariazzo E
AU  - Colamartini F
AU  - Cantale O
AU  - Mogavero A
AU  - Vitale A
AU  - Romano L
AU  - Peroni M
AU  - Rijavec E
AU  - Banini M
AU  - Mazzoni S
AU  - Montrone M
AU  - Pasello G
AU  - Veccia A
AU  - Ogliari FR
AU  - Leo S
AU  - Cortinovis D
AU  - Delmonte A
AU  - Belluomini L
AU  - La Cava G
AU  - Meoni G
AU  - Sini C
AU  - Delcuratolo MD
AU  - Bettini A
AU  - Pagano M
AU  - Genova C
AU  - Russo A
AU  - Pelizzari G
AU  - Tondulli L
AU  - Sergi C
AU  - Roca E
AU  - Bennati C
AU  - Grisanti S
AU  - Stanzione B
AU  - Mariotti S
AU  - Vavalà T
AU  - Soto Parra H
AU  - Ortega C
AU  - Pignataro D
AU  - Lacidogna G
AU  - Pino MS
AU  - Chiari R
AU  - Calabrò L
AU  - Pozzessere D
AU  - Masini S
AU  - Gelibter A
AU  - Scotti V
AU  - Grossi F
AU  - Tiseo M
AU  - Bria E
AU  - Metro G
PY  - 2026
JO  - The oncologist
DO  - 10.1093/oncolo/oyag285
UR  - https://doi.org/10.1093/oncolo/oyag285
ER  -

APA

E, G., F, C., O, C., A, M., A, V., L, R., M, P., E, R., M, B., S, M., M, M., G, P., A, V., FR, O., S, L., D, C., A, D., L, B., G, L. C., G, M., C, S., MD, D., A, B., M, P., C, G., A, R., G, P., L, T., C, S., E, R., C, B., S, G., B, S., S, M., T, V., H, S. P., C, O., D, P., G, L., MS, P., R, C., L, C., D, P., S, M., A, G., V, S., F, G., M, T., E, B., & G, M. (2026). EGFR-mutant NSCLC progressing on first-line osimertinib: rebiopsy in real-world and impact of second-line therapies (the "Rebiopsy on Osi" study).. The oncologist. https://doi.org/10.1093/oncolo/oyag285

Source records